Supplementation with Lactobacillus reuteri or L. acidophilus reduced intestinal shedding of cryptosporidium parvum oocysts in immunodeficient C57BL/6 mice. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Supplementation with Lactobacillus reuteri or L. acidophilus reduced intestinal shedding of cryptosporidium parvum oocysts in immunodeficient C57BL/6 mice.

Cell Mol Biol (Noisy-le-grand). 1999 Sep;45(6):855-63. Unique Identifier : AIDSLINE MED/20007494
Alak JI; Wolf BW; Mdurvwa EG; Pimentel-Smith GE; Kolavala S; Abdelrahman H; Suppiramaniam V; Department of Biology, Tuskegee University, Alabama 36088, USA.; Jalak@acd.tusk.edu


Abstract: The effect of L. acidophilus supplementation to reduce fecal shedding of Cryptosporidium parvum oocysts was compared to L. reuteri using C57BL/6 female mice immunosuppressed by murine leukemia virus (strain LP-BM5) inoculation. After 12 weeks post LP-BM5 inoculation, 15 immunosuppressed mice each were randomly assinged to one of the following treatment groups: historical control (group A), LP-BM5 control (group B), C. parvum (group C), L. reuteri plus C. parvum (group D) or L. acidophilus plus C. parvum (group E). Mice were pre-fed the L. reuteri or L. acidophilus bacteria strains daily for 13 days, challenged with C. parvum oocysts and thereafter fed the specified Lactobacillus regimens daily during the experimental period. Animals supplemented with L. reuteri shed fewer (p<0.05) oocysts on day-7 post C. parvum challenge compared to controls. Mice supplemented with L. acidophilus also shed fewer (p<0.05) oocysts on days 7 and 14 post-challenge compared to controls. Overall, Lactobacillus supplementation reduced C. parvum shedding in the feces but failed to suppress the production of T-helper type 2 cytokines [interleukin-4 (IL-4), IL-8)] which are associated with immunosuppression. Additionally, Lactobacillus supplementation did not restore T-helper type 1 cytokines (interleukin-2 (IL-2) and gamma interferon (IFN-gamma), which are required for recovery from parasitic infections. Altered T-helper types 1 and 2 cytokine production as a consequence of immunodysfunction permitted the development of persistent cryptosporidiosis while mice with intact immune system were refractory to infection with C. parvum. Reduction in shedding of oocysts observed in the Lactobacillus supplemented mice during deminished IL-2 and IFN-gamma production may be mediated by factors released into the intestinal lumen by the Lactobacillus and possibly other host cellular mechanisms. These observations suggest that L. reuteri or L. acidophilus can reduce C. parvum parasite burdens in the intestinal epithelium during cryptosporidiosis and may serve potential benefits as probiotics for host resistance to intestinal parasitic infections. L. acidophilus was more efficacious in reducing fecal shedding than L. reuteri and therefore may also have implication in the therapy of cryptosporidiosis during immunosuppressive states including human AIDS.


Keywords: JOURNAL ARTICLE Animal AIDS-Related Opportunistic Infections/THERAPY Body Weight Cryptosporidiosis/COMPLICATIONS/*THERAPY Cryptosporidium parvum/GROWTH & DEVELOPMENT/*PARASITOLOGY Drinking Eating Feces/PARASITOLOGY Female Intestines/PARASITOLOGY *Lactobacillus Lactobacillus acidophilus Leukemia Viruses, Murine Mice Mice, Inbred C57BL/*PARASITOLOGY/VIROLOGY Murine Acquired Immunodeficiency Syndrome/*COMPLICATIONS/ IMMUNOLOGY/METABOLISM Organ Weight Probiotics/PHARMACOLOGY/*THERAPEUTIC USE Spleen/ANATOMY & HISTOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Virus Shedding

KWDjournalarticleanimalaids-relatedopportunisticinfections/therapybodyweightcryptosporidiosis/complications/KWDtherapycryptosporidiumparvum/growth&development/KWDparasitologydrinkingeatingfeces/parasitologyfemaleintestines/parasitologyKWDlactobacilluslactobacillusacidophilusleukemiaviruses,murinemicemice,inbredc57bl/KWDparasitology/virologymurineacquiredimmunodeficiencysyndrome/KWDcomplications/immunology/metabolismorganweightprobiotics/pharmacology/KWDtherapeuticusespleen/anatomy&histologysupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDvirusshedding
000430
A0040918


Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .